Publish in this journal
Journal Information
Vol. 65. Issue 7.
Pages 679-680 (July 2012)
Vol. 65. Issue 7.
Pages 679-680 (July 2012)
Full text access
Olmesartan for the Prevention or Delay of Diabetic Nephropathy, Some Considerations. Response
Uso de olmesartán en la prevención o retraso de la nefropatía diabética, algunas consideraciones. Respuesta
Luciano Consuegra-Sáncheza,
Corresponding author

Corresponding author:
, Julio Nuñezb, Francisco Picóa, Juan Sanchisb
a Servicio de Cardiología, Hospital General Universitario de Santa Lucía, Cartagena, Murcia, Spain
b Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Valencia, Spain
Related content
Ferrán Catalá-López, Gloria Martín-Serrano, Miguel A. Maciá, Dolores Montero
Article information
Full Text
Download PDF
Full Text

To the Editor,

We appreciate the letter from Catalá-López et al. in response to our recently published article.1 We agree that a relative risk for cardiovascular mortality that is 3 times greater in the intervention group, combining the Randomized Olmesartan And Diabetes Microalbuminuria Prevention (ROADMAP)2 and Olmesartan Reducing Incidence of Endstage renal disease in diabetic Nephropathy Trial (ORIENT)3 results, is not very promising. We find it interesting that the authors reminded us clinicians that olmesartan is authorized “exclusively” for the treatment of arterial hypertension in Spain, as the increased risk of cardiovascular death has mainly been observed in diabetic subjects, normotensive subjects for the most part, who use it to prevent diabetic nephropathy..

However, we would like to add the following considerations to the comments by Catalá-López et al. First, our study included all the articles published up to 30 April 2011 that met a series of criteria explained in detail in the original article.1 The results of the ORIENT3 study were published online (PubMed) 6 months later. Our strategy to include only indexed studies is the strategy used most frequently in systematic reviews. Second, we believe that the observations of our meta-analysis are relevant although, as Catalá-López et al. pointed out, they did not fully answer the question posed. Persistent microalbuminuria is an early sign of nephropathy in type 2 diabetics, and it is associated with the presence of macroalbuminuria and end-stage renal disease.4 In turn, it is accepted that slowing down the progression to end-stage renal disease (eg, by reducing the urinary excretion of albumin) can have a positive impact on the survival prognosis. In this regard, a lot of work has focused on angiotensin II receptor blockers and it is paradoxical that an intervention that can significantly reduce the incidence of microalbuminuria in a little over 3 years is also accompanied by unfavorable outcomes in terms of mortality. A similar finding—unfavorable—was reported in the Irbesartan Patients with Diabetes And MicroAlbuminuria (IRMA-2)5 study. Therefore, we believe that our metaanalysis was relevant in evaluating the “trends” observed in at least 2 previous studies.2, 5 Finally, we also believe that the neutral effect on overall mortality we obtained (relative risk=1.04) in patients with active treatment is a cause for reflection, if not concern..


Corresponding author:

Consuegra-Sánchez L, Sanchis J, Núñez J, Cascón JD, Villegas M, Picó F..
Aumento de mortalidad asociado a olmesartán en pacientes diabéticos para la prevención o retraso de la microalbuminuria: ¿es una causa de preocupación?..
Rev Esp Cardiol. , 65 (2012), pp. 378-380
Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, et al..
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes..
N Engl J Med. , 364 (2011), pp. 907-917
Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al, ORIENT study investigators..
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study..
Diabetologia. , 54 (2011), pp. 2978-2986
Burgess E..
Slowing the progression of kidney disease in patients with diabetes..
J Am Soc Hypertens. , 2 (2008), pp. S30-S37
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P..
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes..
N Engl J Med. , 345 (2001), pp. 870-878
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?